BioAge Labs (BIOA) CFO exercises 3,542 options, now holds 36,575 shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
BioAge Labs, Inc. Chief Financial Officer Dov A. Goldstein exercised stock options for 3,542 shares of common stock at $4.38 per share. Following the exercise, he directly holds 36,575 common shares and 155,833 stock options, which vest in equal monthly installments through their February 17, 2035 expiration.
Positive
- None.
Negative
- None.
Insider Trade Summary
3,542 shares exercised/converted
Mixed
2 txns
Insider
GOLDSTEIN DOV A MD
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 3,542 | $0.00 | -- |
| Exercise | Common Stock | 3,542 | $4.38 | $16K |
Holdings After Transaction:
Stock Option (Right to Buy) — 155,833 shares (Direct, null);
Common Stock — 36,575 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Options Exercised: 3,542 shares
Exercise Price: $4.38 per share
Common Shares Held: 36,575 shares
+3 more
6 metrics
Options Exercised
3,542 shares
Common stock acquired via option exercise on 2026-04-23
Exercise Price
$4.38 per share
Strike price of exercised stock options
Common Shares Held
36,575 shares
Direct common stock ownership after transaction
Options Remaining
155,833 options
Stock options held after transaction
Option Expiration
February 17, 2035
Expiration date of the stock option grant
Vesting Schedule
1/48 monthly
Award vests monthly starting February 1, 2025
Key Terms
Stock Option (Right to Buy), Exercise or conversion of derivative security, vesting, Chief Financial Officer
4 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)" for derivative transaction"
Exercise or conversion of derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
vesting financial
"The option vested or vests as to 1/48th of the total award monthly"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Chief Financial Officer financial
"officer_title: "Chief Financial Officer" for reporting person"
A Chief Financial Officer (CFO) is the person in charge of a company's money and financial planning. They decide how to spend, save, and invest funds to help the company grow and stay stable. Their role is important because good financial decisions keep the company healthy and successful.
FAQ
What did BioAge Labs (BIOA) CFO Dov Goldstein do in this Form 4?
BioAge Labs CFO Dov A. Goldstein exercised stock options to acquire 3,542 shares of common stock at $4.38 per share. This was an option exercise, not an open-market purchase, and reflects compensation becoming actual share ownership under his equity award.
What are the key terms of the BioAge Labs (BIOA) stock options exercised?
The exercised stock options allowed purchase of 3,542 shares at $4.38 per share and expire on February 17, 2035. The award vests monthly in forty‑eight equal installments, starting February 1, 2025, contingent on continued service with BioAge Labs at each vesting date.
Was this BioAge Labs (BIOA) CFO transaction a market buy or a routine option exercise?
This transaction was a routine option exercise, coded “M” as an exercise or conversion of a derivative security. Goldstein converted 3,542 stock options into common shares at the preset $4.38 price, rather than buying shares on the open market.
How many BioAge Labs (BIOA) stock options does the CFO hold after this exercise?
Following the exercise of 3,542 options, Dov Goldstein holds 155,833 stock options. These options relate to BioAge Labs common stock and continue vesting monthly, with the option grant scheduled to expire on February 17, 2035, if not fully exercised before then.